cutoff time point based on PK? [NCA / SHAM]

posted by Biostats – India, 2017-11-26 08:36 (2781 d 06:16 ago) – Posting: # 18006
Views: 4,231

Dear Sir,

Thanks for your prompt response

As per Methylphenidate FDA draft guidance cut-off time point should be Average of Tmax + 2*SD (Average and SD should be calculated from IR portion).

Can we apply this method for EMA submission?

Can we apply reference-scaling for all seven pk parameters or only for pk parameters from first phase i.e. Cmax(1) & AUC(1) as expected large intra-subject variability in first phase?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,698 registered users;
103 visitors (0 registered, 103 guests [including 18 identified bots]).
Forum time: 15:53 CEST (Europe/Vienna)

Anyone who conducts an argument by appealing to authority
is not using his intelligence;
he is just using his memory.    Leonardo da Vinci

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5